In all cancer types, the most widely studied immunotherapeutic agents to date are ICI blocking cytotoxic T lymphocyte-associated molecule-4 (CTLA-4), programmed cell death receptor-1 (PD-1) and programmed cell death ligand-1 (PD-L1). The gene discussed is CD274; the disease is cancer.